Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven cancers, and ELI-008, a multivalent lymph node-targeted AMP peptide vaccine in preclinical studies for the treatment of mutated tumor protein p53-expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts. Show more
451 D Street, Boston, MA, 02210, United States
Market Cap
220.4M
52 Wk Range
$4.70 - $14.93
Previous Close
$12.18
Open
$12.18
Volume
51,357
Day Range
$11.96 - $12.39
Enterprise Value
216.5M
Cash
18.56M
Avg Qtr Burn
-6.797M
Insider Ownership
30.88%
Institutional Own.
13.93%
Qtr Updated
12/31/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
ELI-002 7P Details Pancreatic cancer, Cancer | Phase 2 Data readout | |
ELI-002 2P Details Solid tumor/s, Cancer | Phase 1 Update |
